Citius pharmaceuticals, inc. reports fiscal full year 2022 financial results and provides business update

$41.7 million in cash and cash equivalents as of september 30, 2022; extends runway through december 2023 mino-lok® phase 3 trial closer to completion with 169 patients recruited, 72 failure events and 17 patients in active treatment or pending data review i/ontak bla accepted for filing by the fda; updated pdufa target action date is july 28, 2023 halo-lido phase 2b trial progressed; data readout expected 2h 2023 multiple value-driving catalysts anticipated in 2023, including a potential drug approval and two trial completions cranford, n.j., dec. 22, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended september 30, 2022.
CTXR Ratings Summary
CTXR Quant Ranking